John J. Rossi

CytoGenix, Inc. focuses on development and commercialization of its proprietary technology for identify and silencing disease causing genes and expressing proteins for applications. The company was founded on February 10, 1995 and is headquartered in Houston, TX.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Beckman Research Institute of The City of Hope is a world-class cancer treatment and research center that offers unparalleled patient outcomes. The institute is located in Duarte, CA and has subsidiaries in the United States. The institute is dedicated to making a difference in the lives of people with cancer, diabetes, and other serious illnesses through compassion and discovery. The non-profit company is aggressively pursuing ways to help their patients right now and are a worldwide leader in administering clinical trials. The company's patient care and treatment extend across a broad range of departments and services.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.